Competing interests
ONCOLOGY, GYNECOLOGIC CANCER
MSD supported the study by providing the study drugs (olaparib and pembrolizumab). J.Y.L., B.G.K., and J.W.K. received grants from the MSD during the conduct of the study. J.Y.L. received grants and personal fees from AstraZeneca, Beigene, Bergenbio, Clovis Oncology, Immunogen, Janssen, Merck, Novartis, Roche, Seagen, Synthon, and Takeda. B.G.K. received grants from AstraZeneca, Cellid, and Utilex. J.W.K. received personal fees from AstraZeneca, Janssen, Takeda, GSK, Boryung, CMIC, LG Pharma, and Vifor Pharma. D.S.T. reports personal fees for advisory board membership from AstraZeneca, Bayer, Boehringer Ingelheim, Eisai, Genmab, GSK, MSD, and Roche; personal fees as an invited speaker from AstraZeneca, Eisai, GSK, Merck Serono, MSD, Roche, and Takeda; ownership of stocks/shares of Asian Microbiome Library (AMiLi); institutional research grants from AstraZeneca, Bayer, Karyopharm Therapeutics, and Roche; institutional funding as coordinating PI from AstraZeneca and Bergen Bio; institutional funding as local PI from Bayer, Byondis B.V. and Zeria Pharmaceutical Co Ltd; a previous non-renumerated role as Chair of the Asia- Pacific Gynecologic Oncology Trials Group (APGOT); a previous non-renumerated role as the Society President of the Gynecologic Cancer Group Singapore; non-renumerated membership of the Board of Directors of the GCIG; and product samples from AstraZeneca, Eisai, and MSD (non-financial interest). N.Y.N. received personal fees from AstraZeneca and Pfizer. Otherwise, the authors declare that they have no conflicts of interest.